Journal ArticleDOI
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald,A Compston,Gilles Edan,Donald E. Goodkin,Hans-Peter Hartung,Fred D. Lublin,Henry F. McFarland,Donald W. Paty,Chris H. Polman,Stephen C. Reingold,Magnhild Sandberg-Wollheim,William A. Sibley,Alan J. Thompson,Stanley van den Noort,Brian Y. Weinshenker,Jerry S. Wolinsky +15 more
Reads0
Chats0
TLDR
The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.Abstract:
The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in both time and space. Magnetic resonance imaging is integrated with dinical and other paraclinical diagnostic methods. The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including "monosymptomatic" disease suggestive of MS, disease with a typical relapsing-remitting course, and disease with insidious progression, without clear attacks and remissions. Previously used terms such as "clinically definite" and "probable MS" are no longer recommended. The outcome of a diagnostic evaluation is either MS, "possible MS" (for those at risk for MS, but for whom diagnostic evaluation is equivocal), or "not MS."read more
Citations
More filters
Journal ArticleDOI
Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla.
Nancy L. Sicotte,Rhonda R. Voskuhl,Seth E. Bouvier,Rochelle Klutch,Mark S. Cohen,John C. Mazziotta +5 more
TL;DR: The improved detection ability using high-field MR imaging is prominent even when sequence parameters are optimized around the midfield units, suggesting that multicenter trials using both 1.5 T and 3.0 T instruments may be affected by these sensitivity differences.
Journal ArticleDOI
Effect of Smoking Cessation on Multiple Sclerosis Prognosis
Ryan Ramanujam,Ryan Ramanujam,AK Hedström,Ali Manouchehrinia,Lars Alfredsson,Lars Alfredsson,Tomas Olsson,Matteo Bottai,Jan Hillert +8 more
TL;DR: Evidence is provided that continued smoking is associated with an acceleration in time to SPMS and that those who quit fare better, and it is proposed that patients with MS should be advised to stop smoking once a diagnosis has been made to avoid aggravating MS-related disability.
Journal ArticleDOI
EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses.
Finn Sellebjerg,David Barnes,G. Filippini,R. Midgard,Xavier Montalban,Peter Rieckmann,Krzysztof Selmaj,Leo H. Visser,Per Soelberg Sørensen +8 more
TL;DR: The objective of the task force was to review the literature on treatment of MS relapses to provide evidence‐based treatment recommendations and there is a need for further randomized, controlled trials in order to establish the optimal treatment regimen for relapses of MS.
Journal ArticleDOI
Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis
Maria Trojano,Fabio Pellegrini,Damiano Paolicelli,A Fuiani,G. B. Zimatore,C. Tortorella,Isabella Laura Simone,Francesco Patti,A. Ghezzi,Valentina Zipoli,Paolo Rossi,Carlo Pozzilli,Giuseppe Salemi,Alessandra Lugaresi,Roberto Bergamaschi,Enrico Millefiorini,Marinella Clerico,Giacomo Lus,M. Vianello,Carlo Avolio,Paola Cavalla,Vito Lepore,Paolo Livrea,G. Comi,M. P. Amato +24 more
TL;DR: Evaluating the effectiveness of early IFNβ treatment in definite relapsing‐remitting MS and the optimal time to initiate IFN β treatment with regard to the greatest benefits on disability progression to support greater efficacy of early vs. delayed interferon beta treatment.
Journal ArticleDOI
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
TL;DR: Preliminary evidence suggests that ibudilast seems to act in a neuroprotective fashion as measured by 2 independent MRI outcomes, with a possible beneficial clinical effect on disability progression.
References
More filters
Journal ArticleDOI
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Charles M. Poser,Donald W. Paty,Labe C. Scheinberg,W I McDonald,F A Davis,George C. Ebers,Kenneth P. Johnson,William A. Sibley,Donald H. Silberberg,Wallace W. Tourtellotte +9 more
TL;DR: Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS.
Journal ArticleDOI
The clinical course of neuromyelitis optica (Devic's syndrome)
TL;DR: Clinical, laboratory, and imaging features generally distinguish neuromyelitis optica from MS, and patients with relapsing optic neuritis and myelitis may have neuromyeliitis opticas rather than MS.
Journal ArticleDOI
Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis.
George A. Schumacher,Gilbert Beebe,Robert F. Kibler,Leonard T. Kurland,John F. Kurtzke,Fletcher McDowell,Benedict Nagler,William A. Sibley,Wallace W. Tourtellotte,Thomas L. Willmon +9 more
TL;DR: Since its etiology and pathogenesis have eluded detection, it is not surprising that therapeutic attempts have been empiric and often unscientific.
Journal ArticleDOI
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Frederik Barkhof,Massimo Filippi,David Miller,Philip Scheltens,Adriana Campi,Chris H. Polman,Giancarlo Comi,Herman J. Adèr,N. A. Losseff,Jacob Valk +9 more
TL;DR: It is concluded that a four-parameter dichotomized MRI model including gadolinium-enhancement, juxtacortical, infratentorial and periventricular lesions best predicts conversion to clinically definite multiple sclerosis.
Journal ArticleDOI
MRI in the diagnosis of MS A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT
Donald W. Paty,Joel Oger,Lorne F. Kastrukoff,S. A. Hashimoto,John P. Hooge,Andrew Eisen,K. A. Eisen,S. J. Purves,M. D. Low,V. Brandejs,W. D. Robertson,David Kb Li +11 more
TL;DR: MRI was the best method for demonstrating dissemination in space and laboratory-supported definite MS (LSDMS) could be diagnosed in 85 patients of the total 200, and MRI predicted that diagnosis in 18/19 (95%).
Related Papers (5)
Rating neurologic impairment in multiple sclerosis An expanded disability status scale (EDSS)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more